AU2015304847B2 - Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection - Google Patents

Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection Download PDF

Info

Publication number
AU2015304847B2
AU2015304847B2 AU2015304847A AU2015304847A AU2015304847B2 AU 2015304847 B2 AU2015304847 B2 AU 2015304847B2 AU 2015304847 A AU2015304847 A AU 2015304847A AU 2015304847 A AU2015304847 A AU 2015304847A AU 2015304847 B2 AU2015304847 B2 AU 2015304847B2
Authority
AU
Australia
Prior art keywords
dihydro
methyl
mmol
acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015304847A
Other languages
English (en)
Other versions
AU2015304847A1 (en
Inventor
Katherine Louisa Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2015304847A1 publication Critical patent/AU2015304847A1/en
Application granted granted Critical
Publication of AU2015304847B2 publication Critical patent/AU2015304847B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015304847A 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection Ceased AU2015304847B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
US62/040,488 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Publications (2)

Publication Number Publication Date
AU2015304847A1 AU2015304847A1 (en) 2017-02-23
AU2015304847B2 true AU2015304847B2 (en) 2018-10-25

Family

ID=54072911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015304847A Ceased AU2015304847B2 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection

Country Status (22)

Country Link
US (2) US10702521B2 (enExample)
EP (2) EP3182973B1 (enExample)
JP (2) JP6546654B2 (enExample)
KR (1) KR20170043603A (enExample)
CN (2) CN106659717B (enExample)
AR (1) AR101674A1 (enExample)
AU (1) AU2015304847B2 (enExample)
BR (1) BR112017003705B1 (enExample)
CA (1) CA2958800C (enExample)
CL (1) CL2017000391A1 (enExample)
CO (1) CO2017001658A2 (enExample)
CR (1) CR20170069A (enExample)
DO (1) DOP2017000049A (enExample)
EA (1) EA031589B1 (enExample)
ES (1) ES2759303T3 (enExample)
IL (1) IL250251A0 (enExample)
MX (1) MX2017002321A (enExample)
PE (1) PE20170501A1 (enExample)
PH (1) PH12017500315A1 (enExample)
SG (1) SG11201700566SA (enExample)
TW (1) TW201618779A (enExample)
WO (1) WO2016027249A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101674A1 (es) * 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno
EP3468975B1 (en) 2016-06-08 2020-04-01 Aziende Chimiche Riunite Angelini Francesco A.C.R. New antibacterial compounds
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
BR112021018815A2 (pt) * 2019-04-03 2022-03-03 Glaxosmithkline Ip Dev Ltd Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN114173789A (zh) * 2019-07-05 2022-03-11 葛兰素史克知识产权发展有限公司 用于治疗由生殖支原体引起的感染的组合
US12195458B2 (en) 2019-12-02 2025-01-14 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
JP2023528560A (ja) * 2020-04-02 2023-07-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ゲポチダシンを用いて淋菌感染症を治療するためのレジメン
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
CN115667261A (zh) * 2020-04-29 2023-01-31 葛兰素史克知识产权发展有限公司 吉泊达星的结晶形式
WO2022167515A1 (en) 2021-02-05 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
CN119546302A (zh) 2022-09-26 2025-02-28 葛兰素史密斯克莱知识产权发展有限公司 用于治疗细菌性前列腺炎的吉泊达星
CN121537412B (zh) * 2026-01-16 2026-04-03 南京道尔医药研究院有限公司 一种吉泊达星甲磺酸盐的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931343B (en) 1992-03-06 1993-09-24 Akzo Nv 1,4-dioxino(2,3-b)pyridine derivatives.
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
PL364808A1 (en) 2000-07-21 2004-12-13 Ljudmila Petrovna Maljuk Plate for a stand-up meal
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
AU2002219175A1 (en) 2000-12-21 2002-07-01 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
JP4602903B2 (ja) 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
AU2003303956A1 (en) 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ グループ リミテッド 抗細菌剤
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
EP1784410A4 (en) 2004-08-09 2009-07-15 Glaxo Group Ltd ANTIBACTERIAL AGENTS
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
CA2581057A1 (en) 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528604A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
AU2006230364B2 (en) 2005-03-31 2012-09-13 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
TW200716132A (en) 2005-05-03 2007-05-01 Smithkline Beecham Corp Novel chemical compounds
KR20080016577A (ko) 2005-05-24 2008-02-21 아스트라제네카 아베 항균 활성을 갖는 아미노피페리딘 퀴놀린 및 이들의아자이소스테릭 유사체
CA2608687A1 (en) 2005-05-25 2006-11-30 Actelion Pharmaceuticals Ltd. New antibiotic derivatives
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
HRP20100194T8 (hr) 2005-10-21 2010-06-30 Glaxo Group Limited Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva
US7855201B2 (en) 2005-12-06 2010-12-21 Merck Sharp & Dohme. Corp. Morpholine carboxamide prokineticin receptor antagonists
WO2007071936A1 (en) 2005-12-22 2007-06-28 Glaxo Group Limited Heterocyclic compounds, their preparation and their use as antibacterials
ATE481406T1 (de) 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
EP2029612A1 (en) 2006-06-09 2009-03-04 Glaxo Group Limited Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
PT2137196E (pt) * 2007-04-20 2010-12-16 Glaxo Group Ltd Compostos tricíclicos contendo azoto como agentes antibacterianos
CN102105473B (zh) 2008-05-23 2013-05-08 葛兰素集团有限公司 三环含氮化合物及其作为抗菌剂的用途
AR101674A1 (es) * 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials

Also Published As

Publication number Publication date
JP2017524029A (ja) 2017-08-24
CN106659717B (zh) 2019-09-06
CL2017000391A1 (es) 2017-08-18
US11229646B2 (en) 2022-01-25
AR101674A1 (es) 2017-01-04
WO2016027249A1 (en) 2016-02-25
KR20170043603A (ko) 2017-04-21
US20170304301A1 (en) 2017-10-26
EA201790442A1 (ru) 2017-08-31
TW201618779A (zh) 2016-06-01
JP2019189629A (ja) 2019-10-31
CN106659717A (zh) 2017-05-10
CR20170069A (es) 2017-04-28
PH12017500315A1 (en) 2017-07-10
DOP2017000049A (es) 2017-03-15
US20200330462A1 (en) 2020-10-22
US10702521B2 (en) 2020-07-07
CA2958800A1 (en) 2016-02-25
CA2958800C (en) 2020-10-27
SG11201700566SA (en) 2017-03-30
PE20170501A1 (es) 2017-04-27
EP3182973A1 (en) 2017-06-28
AU2015304847A1 (en) 2017-02-23
EP3639824A1 (en) 2020-04-22
CO2017001658A2 (es) 2017-07-19
MX2017002321A (es) 2017-08-02
CN110403939A (zh) 2019-11-05
EA031589B1 (ru) 2019-01-31
EP3182973B1 (en) 2019-09-18
BR112017003705A2 (pt) 2017-12-05
ES2759303T3 (es) 2020-05-08
BR112017003705B1 (pt) 2022-07-12
JP6546654B2 (ja) 2019-07-17
IL250251A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2008240764C1 (en) Tricyclic nitrogen containing compounds as antibacterial agents
US11229646B2 (en) Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione
US7732460B2 (en) Heterocyclic compounds, their preparation and their use as antibacterials
US20100048544A1 (en) Pyrrolo (3, 2, 1-ij) quinoline-4-one-derivatives for treating tuberculosis
US20100184751A1 (en) Heterocyclic compounds for the treatment of tuberculosis
US20110009394A1 (en) Tricyclic nitrogen compounds and their use as antibacterial agents
HK1138000B (en) Tricyclic nitrogen containing compounds as antibacterial agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired